Idelalisib(Zydelig) is a targeted therapy drug whose price, contraindications, and drug interactions are the focus of both patients and the medical team. Knowing this information can help optimize treatment options and reduce potential risks, helping patients estimate their financial needs before treatment.

How much is a box of Idelalisib tablets?

The price and specifications of Idelalisib tablets need to be comprehensively evaluated in combination with the production information and treatment cycle of the original drug.

Drug prices and specifications

The original drug of Idelalisib, produced by Gilead in the United States, is 150mg×60 tablets per box, and the price is 6,530 US dollars. Each box of medication meets the treatment needs for one month (150 mg twice daily). At present, the drug is not marketed in China, and it needs to be obtained through formal cross-border medical channels, and patients need to be wary of counterfeit drugs.

Economics and cost management

Based on continued treatment until disease progression or intolerable toxicity, the monthly cost is approximately $6,530. Some patients may need to adjust the dose or discontinue the drug due to adverse reactions, and the actual cost of treatment may fluctuate. Patients are advised to plan their medical budget in advance and communicate with their insurance company or medical provider about cost support options.

When purchasing, you need to check the integrity of the drug packaging and confirm that the bottle is engraved with the words "GSI" and "150" to avoid improper storage or transportation problems affecting the efficacy of the drug.

Are there any contraindications to the use of Idelalisib?

Contraindications to Idelalisib involve the patient's health and medication restrictions, and the patient should follow the doctor's instructions strictly to avoid serious adverse effects.

Absolute contraindications

It is contraindicated in patients who are allergic to the components of Idelalisib or have a history of severe hypersensitivity reactions (e.g., anaphylactic shock). It is contraindicated in patients with a history of toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome (SJS). Patients with active infection (e.g., uncontrolled pneumonia, sepsis) or confirmed Pneumocystis jirovecii pneumonia (PJP) should be permanently discontinued.

Relative contraindications and risk groups

In patients with abnormal liver function, baseline ALT/AST exceeds 2.5 times the upper limit of normal or bilirubin > 1.5 times. Pregnant and lactating women need strict contraception and avoid breastfeeding due to the risks to the fetus and baby. Elderly patients (≥ 65 years old) have a high incidence of adverse reactions, and need to adjust the dose and strengthen monitoring under the guidance of a doctor.

If intestinal perforation, severe neutropenia (<1.0 Gi/L), or grade 3 or higher skin reactions occur during treatment, the drug should be discontinued immediately and supportive care should be received.

What drugs does Idelalisib interact with?

Drug interactions with Idelalisib may affect efficacy or increase toxicity, and patients should be fully informed about their use history to avoid risks.

CYP3A enzyme-related drugs

Potent CYP3A inhibitors (eg, ketoconazole, clarithromycin) may increase the plasma concentration of Idelalisib, increasing the risk of hepatotoxicity; Potent CYP3A inducers (eg, rifampicin, carbamazepine) may reduce drug concentrations and reduce efficacy. Liver function and response should be closely monitored for response to these drugs in combination, and dose adjustment should be adjusted as necessary.

Hepatotoxic drugs and immunomodulators

Avoid combining with hepatotoxic drugs such as acetaminophen and isoniazid to prevent the risk of superimposed liver injury. Immunosuppressants (e.g., corticosteroids) may exacerbate the risk of infection, and infection control should be prioritized before initiation of therapy. When used in combination with antidiarrheal drugs, it should be noted that the diarrhea associated with Idelalisib does not respond well to antikinetic drugs, which may delay the diagnosis of the disease.

Idelalisib should be stored at 15-30°C to avoid high temperatures or humidity. During treatment, it is recommended to record the names and doses of all concomitant drugs, and regularly review liver enzymes, blood routine, and infection indicators. Patients who develop a fever, rash, or difficulty breathing should seek immediate medical attention and stop taking the medication.

A correct understanding of drug interactions and contraindications, combined with the individualized guidance of the medical team, is the main part of ensuring the safety of the treatment of Idelalisib. Patients and their families need to actively participate in treatment decision-making and timely feedback on medication response to achieve the best clinical treatment effect.